|
|
|
|
Combined knockdown or dual-inhibition of BRD4 and CBP/p300 down-regulated CUB domain-containing protein 1 (CDCP1) transcription and downstream PI3K/AKT and/or SRC/MAPK signaling pathways in CRPC cells much more so than single-protein perturbation. [Oncogene]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
The secretome of CRPC cells mediated neo-angiogenesis in an androgen-dependent manner, which was counteracted by atraric acid.
[Oncogene]
|
|
|
|
|
|
Transcriptional heterogeneity was analyzed in pools of ten DU145 and PC3 cells with multiplex gene expression analyses and illustrated a higher degree of heterogeneity within the aldehyde dehydrogenase-positive (ALDH+) population that even increased upon irradiation in comparison with ALDH− cells.
[Molecular Cancer Research]
|
|
|
|
|
|
Stimulation of arginine vasopressin receptor type 2 (AVPR2) with a selective agonist desmopressin promoted CRPC cell proliferation through cAMP/protein kinase A signaling, consistent with AVPR2 coupling to the G alpha s subunit.
[Molecular Cancer Research]
|
|
|
|
|
|
Researchers determined whether the non-drug efflux function of ATP binding cassette subfamily C member 5 (ABCC5) affected enzalutamide resistance. The ABCC5 expression data in patients with prostate cancer were retrieved from The Cancer Genome Atlas and Gene Expression Omnibus.
[Cell Death Discovery]
|
|
|
|
|
|
Scientists analyzed and demonstrated that two enantiomers of naftopidil, an α1D/1A-adrenoceptor blocker, induced expression and activity of UDP-glucuronosyltransferase 2B (UGT2B) in benign prostate hyperplasia rat prostate models as well as UGT2B15 in human prostate cells, BPH-1.
[Journal of Steroid Biochemistry and Molecular Biology]
|
|
|
|
|
|
Cellular proliferation, qPCR, Western blot and apoptosis assays were performed to investigate the molecular mechanism of selected miRNAs in the prostate cancer cells.
[Life Sciences]
|
|
|
|
|
|
The authors showed that the combination of tetracyclic aromatic core and docetaxel had strong synergism in inhibiting prostate cancer cell survival.
[Bioorganic & Medicinal Chemistry]
|
|
|
|
|
|
A 2RRV1 mouse xenograft model was established to detect the effect of SBD on prostate cancer (PCa). Angiogenesis was analyzed by coculturing PCa cell lines and human umbilical vein endothelial cells. [BMC Complementary and Alternative Medicine]
|
|
|
|
|
|
|
|
The authors summarize the challenges targeting the tumor environments, and emphasize that continued exploration of tumor heterogeneity is needed in order to offer a personalized therapy for advanced prostate cancer patients.
[npj Precision Oncology]
|
|
|
|
|
|
Scientists review the potential etiologies of cognitive decline in patients with prostate cancer, including the potential role of androgen receptor pathway inhibitors. [CNS Drugs]
|
|
|
|
|
|
|
|
Bayer announced the US FDA has accepted a sNDA and granted Priority Review for the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of mHSPC. [Bayer AG]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
Oslo University Hospital – Oslo, Norway
|
|
|
|
|
|
|
University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|
|
|
University Hospital Frankfurt – Frankfurt, Germany
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|